EP0037078B1 - Verfahren zur Wärmebehandlung einer wässrigen Lösung, die den menschlichen Blutkoagulationsfaktor XIII enthält - Google Patents

Verfahren zur Wärmebehandlung einer wässrigen Lösung, die den menschlichen Blutkoagulationsfaktor XIII enthält Download PDF

Info

Publication number
EP0037078B1
EP0037078B1 EP81102255A EP81102255A EP0037078B1 EP 0037078 B1 EP0037078 B1 EP 0037078B1 EP 81102255 A EP81102255 A EP 81102255A EP 81102255 A EP81102255 A EP 81102255A EP 0037078 B1 EP0037078 B1 EP 0037078B1
Authority
EP
European Patent Office
Prior art keywords
acid
factor xiii
aqueous solution
heat treatment
solution containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP81102255A
Other languages
English (en)
French (fr)
Other versions
EP0037078A2 (de
EP0037078A3 (en
Inventor
Tsunekazu Fukushima
Tomiyuki Matsunaga
Satoshi Funakoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Publication of EP0037078A2 publication Critical patent/EP0037078A2/de
Publication of EP0037078A3 publication Critical patent/EP0037078A3/en
Application granted granted Critical
Publication of EP0037078B1 publication Critical patent/EP0037078B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a process of heat treatment to inactivate the hepatitis virus in an aqueous solution the human blood coagulation factor XIII.
  • the blood coagulation factor XIII (hereinafter referred to briefly as factor XIII) participates in the formation of a stable fibrin polymer in the final stage of blood coagulation mechanism, and is also called fibrin stabilizing factor. Under normal conditions it exists in an inactive form in the blood. However, in the event of formation of thrombin upon coagulation of blood after hemorrhage, the factor XIII becomes activated by the acti on of thrombin and calcium ion and strives for the stabilization of fibrin. Therefore, in a blood suffering from diminution or deficiency of the factor XIII, although the coagulation time shows a normal threshold, the formed fibrin clot is fragile, giving rise to characteristic phenomena such as secondary hemorrhage.
  • the clinical applications of the factor XIII preparations include not only treatment for disorders due to congenital or acquired deficiency or diminution in factor XIII but also promotion of wound healing after surgical operations in a broad range.
  • the factor XIII which is the subject of this invention, is also one of the human serum protein preparations and is likewise subject to contamination with hepatitis virus.
  • the infective activity of hepatitis virus in serum protein preparations in general, particularly in albumin preparations may be controlled by the heat treatment at 60°C for 10 hours without causing the denaturation of albumin. Since the albumin preparation subjected to such a heat treatment has been clinically used with safety, the method of inactivating the hepatitis virus by the heat treatment at 60°C for 10 hours is now being adapted to other human serum protein preparations. However, in order to apply such a heat treatment, the substance being treated must be stable to the treatment.
  • US-A-3,904,751 relates to a process for isolating Factor XIII for a human placenta.
  • the process comprises subjecting a human placenta as starting material to extraction with a sodium chloride aqueous solution, precipitation with diamino-ethoxy-acridine lactate (Rivanol®), a lower alcohol fractionation and purification by .
  • e-amino-caproic acid is contained in a developer and glucose is contained in a dialyzing liquid. That is, these substances are not used as a stabilizer at heat-treatment for inactivating hepatitis virus as in case of the present invention.
  • US-A-3,931,399 relates to a process for isolating Factor XIII from human placenta.
  • Said process comprises extracting human placenta with sodium chloride solution, adding diamino-ethoxy-acridine lactate (Rivanol®); recovering the resultant precipitate and dissolving it in dilute alkali metal chloride solution containing a complexing agent; adding a quaternary ammonium base to the solution to precipitate inactive materials; precipitating the active principal from solution with Rivanol®; again dissolving the precipitate in dilute alkali metal chloride solution containing a complexing agent; reprecipitating the active principal by adding solid ammonium sulfate; forming a paste between the precipitate and a dilute solution of a complexing agent; dialyzing the paste; gel filtering the dialyzed product; precipitating the active principal from the active fractions which ammonium sulfate; dissolving the precipitate in a neutral tris-
  • glucose is added as a stabilizer of Factor XIII merely in the form of a solution as oppposed to the present invention, where glucose is added as a stabilizer of Factor XIII during the heat-treatment for the inactivation of the hepatitis virus.
  • EP-A-0011739 relates to a process for concentrating blood coagulation Factor XIII derived from human placenta, which comprises removing a fraction precipitated from a crude globulin fraction obtained from human placenta at a pH of 6 to 9 in a concentration of 4 to 9% (W/V) of alkylene oxide polymer or copolymer having a molecular weight of 2,000 to 20,000, and then collecting the fraction precipitated at the same pH in a concentration of 20 to 30% (W/V) of the above-mentioned polymer or copolymer, and subjecting the resulting concentrated Factor XIII to heat-treatment for inactivating the hepatitis virus in the presence of 10-20% neutral amino acid, monosaccharide or sugar alcohol.
  • the present invention relates to a process for heat-treatment of Factor XIII-containing aqueous solution for inactivating hepatitis virus in the copresence of 10-30% W/V of a principal stabilizer selected from neutral amino acid, monosaccharide and sugar alcohol and 10-30% W/V of auxiliary stabilizer selected from alkali metal and alkaline earth metal salts or organic carboxylic acids having 3-10 carbon atoms.
  • a principal stabilizer selected from neutral amino acid, monosaccharide and sugar alcohol
  • auxiliary stabilizer selected from alkali metal and alkaline earth metal salts or organic carboxylic acids having 3-10 carbon atoms.
  • EP-A-0018561 discloses a process for heat-treatment of an aqueous solution containing blood coagulation factor II, VIII, XIII and anti- thrombin III as well as plasminogen for the purpose of inactivating hepatitis virus in the presence of an amino acid, monosaccharide, oligosaccharide or sugar alcohol.
  • the present invention relates to a process for heat-treatment of Factor XIII comprising subjecting the solution containing Factor XIII in the presence of an auxiliary stabilizer selected from alkali metal and alkaline earth metal salts of organic carboxylic acids having 3-10 carbon atoms in addition to the same stabilizer as used in the reference.
  • the present inventors subsequently found that in the above method of heat stabilization, the heat stability of factor XIII could be further improved by the supplementary addition of a specific organic carboxylic acid salt.
  • the present invention has been accomplished on the basis of said finding.
  • An object of this invention is to provide a novel heat treatment process in which the inactivation treatment of hepatitis virus in an aqueous solution containing the human blood coagulation factor XIII is carried out under those conditions which increase the thermal stability of said factor.
  • a process for heat treatment characterized in that the heat treatment at 50° to 80°C of an aqueous solution containing the human blood coagulation factor XIII is carried out for 3 to 15 hours in the presence of 10 to 30% (W/V) of a principal stabilizer selected from the group consisting of neutral amino acids, monosaccharides and sugar alcohols and 10 to 30% (W/V) of an auxiliary stabilizer selected from alkali metal and alkaline earth metal salts of organic carboxylic acids having 3 to 10 carbon atoms.
  • a principal stabilizer selected from the group consisting of neutral amino acids, monosaccharides and sugar alcohols
  • an auxiliary stabilizer selected from alkali metal and alkaline earth metal salts of organic carboxylic acids having 3 to 10 carbon atoms.
  • the factor XIII being heat treated is subject to no particular limitation, so far as it is originated from man. It is contained in blood plasma, platelet and placenta in comparatively large quantities and methods for its recovery from respective materials have been known [Loewy, A.G., Journal of Biological Chemistry, 236, 2625 (1961); Januszko, B.T., Nature, 191, 1093 (1961); Bohn, V.H., Blut, 25, 235 (1972)]. Of these materials, because of their high prices, blood plasma and platelet are unsuitable for the large scale production of factor XIII. Conversely, the placenta contains a comparatively large quantity of factor XIII and is easily available. Therefore, the recovery from the placenta is attracting most attention at present.
  • Preparation of the factor XIII from the placenta can be carried out by several methods such as a method for purifying the factor XIII by a combined procedure involving gel filtration and fractionations using ammonium sulfate, 2- ethoxy-6,9-diaminoacridine lactate (acrinol) and alcohol [Blut, 25, 235 (1972)]; a method utilizing principally the ammonium sulfate fractionation technique (Japanese Patent Application "Kokai” (Laid-open) No. 59,018/1978), and a fractionation method employing an alkylene oxide polymer (Japanese Patent Application "Kokai” (Laid-open) No. 64,522/1980, European Patent Application EP-A-11739.
  • factor XIII degree of purification of factor XIII is not specifically restricted, it is desirable to use an aqueous solution of factor XIII having an activity of 5 to 500 units/ml, as assayed by the method described in Thrombosis, Diathesis Haemorrhagica, 23, 455 (1970).
  • the factor XIII content of the aqueous solution to be heat- treated is preferably 0.1 to 10% (W/V) in terms of protein and the pH of the solution is generally 5 to 10, preferably 6.5 to 8.5 and adjusted most preferably with a suitable buffer solution of a low salt concentration.
  • the neutral amino acids, monosaccharides and sugar alcohols for use as principal stabilizers are described in detail in Japanese Patent Application "Kokai” (Laid-open) No. 59,018/1978.
  • Nonlimitative examples include neutral amino acids such as glycine and analine, monosaccharides such as glucose, xylose, and fructose, and sugar alcohols such as mannitol, galactitol, glucosaminitol, sorbitol, and galacto- aminitol. They may be used each alone or in combinations.
  • the amount to be added of principal stabilizers is generally 10% to 30% (W/V) in practice. If present in an amount less than 10% (W/V), the principal stabilizers will exhibit only unsatisfactory stabilizing effect.
  • the organic carboxylic acid having 3 to 10 carbon atoms is used in the form of a salt as the auxiliary stabilizer according to this invention is a hydrocarbon moiety combined with a carboxyl group.
  • the hydrocarbon moiety may be saturated or unsaturated. Examples of such hydrocarbon moieties include alkyl groups, aryl groups (e.g. phenyl group) and aralkyl groups.
  • the number of carboxyl group may be singular or plural, preferably one or two.
  • the carboxylic acid may contain a hydroxyl group as substituent.
  • the salt of said organic carboxylic acid to be used in the present process may be any so far as it is physiologically acceptable, alkali metal salts (e.g. sodium salt and potassium salt) and alkaline earth metal salts (e.g. calcium salt) are employed and sodium salt and potassium salt are most preferred.
  • Suitable organic carboxylic acid salts include physiologically acceptable alkali metal and alkaline earth metal salts, preferably alkali metal salts (sodium salts and potassium salts) or organic carboxylic acids having 3 to 10 carbon atoms, preferably of propanoic acid, butanoic acid, pentanoic acid, caprylic acid, caproic acid, malonic acid, succinic acid, glutaric acid, adipic acid, citric acid and mandelic acid. These salts are used each alone or in combinations.
  • the amount to be added of an organic carboxylic acid salt is 10% to 30% (W/V). If the amount is below 10% (W/V), the effectiveness as an auxiliary stabilizer will be unsatisfactory.
  • the temperature of heat treatment is 50° to 80°C, preferably 60°C and the time of heating is 3 to 15 hours, preferably 10 hours.
  • the aqueous solution containing the factor XIII shows an electric conductivity two to five times as high as that of untreated solution. Consequently, before purification, the heat- treated aqueous solution is dialyzed, diluted, or centrifuged to separate the factor XIII as a precipitate. Then the purification may be performed in known ways. If the recovered factor XIII has a sufficiently high purity, it is made into medicinal preparations by customary pharmaceutical procedures such as sterile filtration, dispensation and lyophilization.
  • factor XIII In the case of crude factor XIII, it is purified by a combination of known purification procedures for factor XIII, such as chromatography with an anion exchanger, treatment with a molecular sieve, and fractionation by use of PEG, acrinol or the like.
  • a preparation of human factor XIII which has been recovered from a HBsAg (hepatitis virus antigen)-positive blood plasma was heat treated at 60°C for 10 hours under the conditions as herein specified.
  • a portion of the preparation corresponding to a factor XIII activity of 500 unit was inoculated into a chimpanzee to observe the onset of hepatitis. After one month, no sign of hepatitis was observed.
  • the heat treatment process of this invention is capable of perfectly inactivating the infectivity of hepatitis virus which is liable to contaminate the factor XIII preparation, a precious blood preparation, thereby causing no loss in factor XIII activity.
  • the heat treatment according to this invention therefore, has a remarkable advantage in the commercial production of factor XIII preparations involving a virus inactivation step.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (6)

1. Verfahren zur Wärmebehandlung einer wäßrigen Lösung, die den menschlichen Blutkoagulationsfaktur XIII enthält, wobei man die Wärmebehandlung bei 50 bis 80°C mit einer wäßrigen Lösung, die den menschlichen Blutkoagulationsfaktur XIII enthält, während 3 bis 15 Stunden in Gegenwart von 10 bis 30% (Gew./Vol.) von mindestens einer Hauptstabilisatorsubstanz aus der Gruppe neutrale Aminosäuren, Monosaccharide und Zuckeralkohole durchführt, dadurch gekennzeichnet, daß man zusätzlich 10 bis 30% (Gew./Vol.) mindestens einer Nebenstabilisatorsubstanz aus der Gruppe Alkalimetallsalze und Erdalkalimetallsalze von organischen Carbonsäuren mit 3 bis 10 Kohlenstoffatomen zusetzt.
2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Salze der organischen Carbonsäuren physiologisch verträgliche Salze von Propionsäure, Buttersäure, Valeriansäure (Pentansäure), Caprylsäure, Capronsäure, Malonsäure, Bernsteinsäure, ' Glutarsäure, Adipinsäure, Citronensäure und Mandelsäure sind.
3. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß das physiologisch verträgliche Salz ein Natrium- oder Kaliumsalz ist.
4. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die neutrale Aminosäure Glycin oder Alanin ist.
5. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Monosaccharid, Glukose, Xylose oder Fructose ist.
6. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß der Zuckeralkohol Mannit, Galactit, Glucosamin, Sorbit oder Galactosamin ist.
EP81102255A 1980-03-27 1981-03-25 Verfahren zur Wärmebehandlung einer wässrigen Lösung, die den menschlichen Blutkoagulationsfaktor XIII enthält Expired EP0037078B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4005080A JPS56135418A (en) 1980-03-27 1980-03-27 Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JP40050/80 1980-03-27

Publications (3)

Publication Number Publication Date
EP0037078A2 EP0037078A2 (de) 1981-10-07
EP0037078A3 EP0037078A3 (en) 1982-01-13
EP0037078B1 true EP0037078B1 (de) 1984-03-14

Family

ID=12570076

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81102255A Expired EP0037078B1 (de) 1980-03-27 1981-03-25 Verfahren zur Wärmebehandlung einer wässrigen Lösung, die den menschlichen Blutkoagulationsfaktor XIII enthält

Country Status (4)

Country Link
US (1) US4327086A (de)
EP (1) EP0037078B1 (de)
JP (1) JPS56135418A (de)
DE (1) DE3162578D1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
JPS57140724A (en) 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4845074A (en) * 1982-05-13 1989-07-04 Cedars Sinai Medical Center Heat treatment of Factor VIII
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4556558A (en) * 1982-05-13 1985-12-03 Cedars-Sinai Medical Center Treatment of factor VIII concentrate to minimize the affect of undesirable microorganisms
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
JPS5967228A (ja) * 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4585654A (en) * 1983-04-29 1986-04-29 Armour Pharmaceutical Co. Process for pasteurizing fibronectin
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US5176921A (en) * 1983-05-02 1993-01-05 Diamond Scientific Co. Method of blood component decontamination by glucose addition
AT382078B (de) * 1983-05-31 1987-01-12 Immuno Ag Verfahren zur herstellung von praeparationen aus menschlichem blutplasma
DE3330770A1 (de) * 1983-08-26 1985-03-14 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von humanplasma
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
DE3419581A1 (de) * 1984-05-25 1985-11-28 Behringwerke Ag, 3550 Marburg Verfahren zur gewinnung einer faktor xiii-praeparation sowie ihre verwendung
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
WO1987005220A1 (en) * 1986-03-10 1987-09-11 Rubinstein Alan I A method for treating gammaglobulin
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
EP0357724B1 (de) * 1988-02-18 1992-12-02 Baxter International Inc. Stabilisierte heparinlösung
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
JPH0650999B2 (ja) * 1988-09-12 1994-07-06 日本商事株式会社 血液凝固因子安定化法
FR2650508A1 (fr) * 1989-08-01 1991-02-08 Fondation Nale Transfusion San Colle pasteurisee pour reunir des tissus humain ou animal
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
JPH04507108A (ja) * 1990-05-07 1992-12-10 バクスター、インターナショナル、インコーポレイテッド 安定化されたヘパリン溶液
JP3337488B2 (ja) * 1992-03-06 2002-10-21 アベンティス ファーマ株式会社 切迫流産治療剤
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
US7297716B2 (en) * 2000-10-23 2007-11-20 Shanbrom Technologies, Llc Enhanced production of blood components, blood cells and plasma without freezing
US6881731B1 (en) * 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
US7411006B2 (en) * 2000-10-23 2008-08-12 Shanbrom Technologies, Llc Enhanced production of blood clotting factors and fibrin fabric
US8389687B2 (en) 2000-10-23 2013-03-05 Shanbrom Technologies, Llc Polyvinylpyrrolidone cryoprecipitate extraction of clotting factors
MXPA03007069A (es) * 2001-02-07 2004-10-15 Shanbrom Tech Llc Acido carboxilico tal como acido citrico para desinfectar o mejorar la produccion de productos sanguineos tales como el plasma, crioprecipitado y/o plaqueta.
JP4680398B2 (ja) * 2001-02-09 2011-05-11 朝日印刷株式会社 包装用箱と物品収容枠
EP1532983A1 (de) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
JP4868457B2 (ja) * 2007-06-28 2012-02-01 シグマ紙業株式会社 包装容器
EP2268267B1 (de) * 2008-04-21 2017-06-14 Novo Nordisk Health Care AG Trockene transglutaminase-zusammensetzung
JP5069661B2 (ja) * 2008-10-22 2012-11-07 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
CA2788863C (en) 2010-02-04 2020-07-07 Reinhard Franz Bolli Immunoglobulin preparation
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
CN102924562B (zh) * 2012-11-19 2014-07-23 成都蓉生药业有限责任公司 一种人凝血因子ⅷ的干热处理稳定剂及其用途
CN105879038B (zh) * 2016-05-27 2020-03-27 成都蓉生药业有限责任公司 一种制备人凝血酶原复合物的干热处理稳定剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904751A (en) * 1970-12-22 1975-09-09 Behringwerke Ag Process for isolating a fibrin stabilizing factor from human placenta
US3931399A (en) * 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
JPS51118820A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable macroglobulin
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
JPS6029687B2 (ja) * 1978-11-07 1985-07-12 株式会社ミドリ十字 ヒト胎盤由来血液凝固第１０３因子の濃縮液の製造方法
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
EP0037078A2 (de) 1981-10-07
EP0037078A3 (en) 1982-01-13
DE3162578D1 (en) 1984-04-19
JPS56135418A (en) 1981-10-22
JPS6236493B2 (de) 1987-08-07
US4327086A (en) 1982-04-27

Similar Documents

Publication Publication Date Title
EP0037078B1 (de) Verfahren zur Wärmebehandlung einer wässrigen Lösung, die den menschlichen Blutkoagulationsfaktor XIII enthält
US4446134A (en) Process for heat treatment of aqueous solution containing human blood coagulation factor VIII
CA1126652A (en) Antithrombin preparation and process for the production thereof
US4424206A (en) Process for heat treatment of aqueous solution containing cold insoluble globulin to inactivate hepatitis virus
US4470969A (en) Process for producing a concentrate of coagulation factors VII and VIIa
AU2001273907A1 (en) A method of producing IgG
EP1268551A2 (de) EINE METHODE ZUR HERSTELLUNG VON IgG
JPS5944320A (ja) Ｃ１不活性化剤の調製方法
JPH0764751B2 (ja) アルフア−１−プロテイナ−ゼ阻害剤の製造法
AU549584B2 (en) Heat stabilization of plasma proteins
EP0252392B1 (de) Virale Inaktivierung und Reinigung von aktiven Proteinen
EP0011739B1 (de) Verfahren zur Gewinnung von Blutkoagulations-Faktor XIII aus menschlicher Plazenta
RU2198668C2 (ru) Способ получения раствора гамма-глобулина, предназначенного для внутривенного введения, и продукт, получаемый этим способом
US6063909A (en) Preparation of factor IX
EP0117064A2 (de) Verfahren zur Hitzebehandlung vom Blutgerinnungsfaktor VIII
US4473553A (en) Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa
US4822872A (en) Method of purifying factor VIII
CA1182748A (en) Method for synthesizing procoagulant factor viii activity
JPS61189228A (ja) 血液凝固第８因子製剤の製法
WO1998030230A1 (fr) Compositions proteinees et procede de production
JPH04502324A (ja) 純粋なｉ因子蛋白質および該蛋白質の製造方法
DK175644B1 (da) Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter
JPH03106824A (ja) 血液凝固第ｘ３因子の加熱処理方法
JP2678193B2 (ja) ヒト血漿由来血液凝固第ｘ▲ｉｉｉ▼因子の製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): CH DE FR GB LI SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 19810925

AK Designated contracting states

Designated state(s): CH DE FR GB LI SE

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): CH DE FR GB LI SE

REF Corresponds to:

Ref document number: 3162578

Country of ref document: DE

Date of ref document: 19840419

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19920310

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19920316

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19920319

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19920326

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19920430

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19930325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19930331

Ref country code: CH

Effective date: 19930331

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19930325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19931130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19931201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 81102255.7

Effective date: 19931008